Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACKR3 | P25106 | 2/20 | 0.49 |
| ▸ | CTSD | P07339 | 2/20 | 0.49 |
| ▸ | BACE1 | P56817 | 2/20 | 0.49 |
| ▸ | BACE2 | Q9Y5Z0 | 2/20 | 0.49 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.48 |
| ▸ | RORC | P51449 | 3/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.47 |
| ▸ | CNR1 | P21554 | 1/20 | 0.46 |
| ▸ | CNR2 | P34972 | 1/20 | 0.46 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.46 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.46 |
| ▸ | ACACB | O00763 | 1/20 | 0.46 |
| ▸ | GRM5 | P41594 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2861620 | 0.85 | CTRB1 (0.51) | PIN1ALDH1A1 | |
| SCHEMBL5462314 | 0.83 | NPC1 (0.56) | ACKR3GRM5 | |
| SCHEMBL2857688 | 0.83 | MEN1 (0.66) | ACKR3CTSDBACE1BACE2GPR139 | |
| SCHEMBL5453401 | 0.79 | ACKR3 (0.46) | ACKR3CTSDBACE1BACE2PIN1 | |
| SCHEMBL5127227 | 0.79 | MME (0.43) | ACKR3PIN1RORCEPHX1GPR139 | |
| SCHEMBL2867569 | 0.78 | MEN1 (0.54) | ACKR3CTSDBACE1BACE2MEN1 | |
| SCHEMBL2853485 | 0.77 | NPC1 (0.51) | BACE1S1PR3MEN1ALDH1A1KMT2A | |
| SCHEMBL26407280 | 0.75 | RAB9A (0.69) | ACKR3GRM5 | |
| SCHEMBL2861403 | 0.75 | L3MBTL1 (0.49) | ACKR3EPHX1ALDH1A1 | |
| SCHEMBL23279644 | 0.73 | GPR132 (0.58) | PIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2253328-A1 | Cycloalkyl inhibitors of potassium channel function | Bristol-Myers Squibb Company (US) | 2010-11-24 | — | — | EP | disclosed |
| US-20070142333-A1 | CYCLOALKYL INHIBITORS OF POTASSIUM CHANNEL FUNCTION | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142333-A1 | CYCLOALKYL INHIBITORS OF POTASSIUM CHANNEL FUNCTION | KCNJ2, KCNN3, KCNQ5 | ACKR3 1451/4885CTSD 3981/4885BACE1 2120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.